Brought to you by 
Actelion spin-out Idorsia completes CHF1.19bn IPO on SIX
20 Jun 2017
Executive Summary
Actelion spin-out Idorsia Pharmaceuticals Ltd. (discovery and development of small molecule therapeutics) grossed CHF1.19bn ($1.23bn) in an initial public offering on the SIX Swiss Exchange through the sale of 119mm registered shares at a debut price of CHF10.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Actelion spin-out Idorsia completes CHF1.19bn IPO on SIX
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice